Pre-cachexia in patients with stages I–III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system-Reference-Cited by-同舟云学术

Pre-cachexia in patients with stages I–III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system

Published:2012-04 Issue:1 Volume:76 Page:112-117
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Op den Kamp C.M.,Langen R.C.,Minnaard R.,Kelders M.C.,Snepvangers F.J.,Hesselink M.K.,Dingemans A.C.,Schols A.M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Definition and classification of cancer cachexia: an international consensus;Fearon;Lancet Oncol,2011

2. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?;Ross;Br J Cancer,2004

3. Cachexia in cancer patients;Tisdale;Nat Rev Cancer,2002

4. Cachexia: prevalence and impact in medicine;Tan;Curr Opin Clin Nutr Metab Care,2008

5. Cachexia as a major underestimated and unmet medical need: facts and numbers;von Haehling;J Cachex Sarcopenia Muscle,2010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine learning to identify precachexia and cachexia: a multicenter, retrospective cohort study;Supportive Care in Cancer;2024-09-03

2. Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool;Journal of Cancer Research and Clinical Oncology;2024-05-09

3. Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study;Cancers;2023-09-01

4. Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene;Frontiers in Cell and Developmental Biology;2022-09-08

5. Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial;Cancer;2022-06-21